Hi Gyro, I tend to feel that the report is conveniently timed. I think your sceptical reasoning is valid, but I also think that even if CE mark is achieved this type of report will get shareholders keen to fork out their hard earned in a capital raising in the near future. The company will still need lots of money and time to develop this product. Who knows, they might even need more $ just to get the CE mark over the line.
Although it is nice to dream that this will start making huge sales immediately, I think the reality is that the existing data is thin and they will need a whole lot more of it before they will convince oncologists to treat their patients with this device.
If they can partner with some big pharma that would be great, but why would big pharma partner Oncosil based on limited data? More likely in my opinion that us investors will need to stump up the cash to complete more in depth trials. Maybe good results from those trials could attract a partner. Either way you look at it though, millions of $ will be needed to fund more trials and to market this effectively.
Who knows. I wish all the best of luck.
OSL Price at posting:
17.5¢ Sentiment: Hold Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)